A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

Marijuana Moment reports a Texas Senate candidate’s alcohol-linked cash haul while opposing cannabis reform—plus new research on teen use and clinical science DMVers should track.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

MAPS linked with New Jersey’s HoneyProjects to bring education into a dispensary setting—its first retail cannabis partnership in 40 years—and it could reshape how patients learn.

What a World Cup controversy reveals about psychedelics, patents, and power—and why DMV patients should watch how culture gets packaged into products and protocols.

A tightly controlled New Zealand program lets two psychiatrists prescribe pharmaceutical-grade MDMA for select adults with PTSD. Here’s how it works, the evidence behind it, and what DMV readers should watch.

FDA guidance, Phase 3 results and VA-led training signal psychedelic therapies edging closer to clinics. Here’s what practitioners—and DMV patients—should know now.

Power dynamics don’t disappear when the music starts. Here’s how to spot orange and red flags in psychedelic and plant ceremonies—and how our DMV community can respond with care.

Resilient resubmits MDMA-assisted therapy to FDA, Definium reports positive oral LSD Phase 3 data in GAD, and Canada funds a C$24M cannabis–brain health consortium.